Theresa L. Werner

University of Opole — Poland

Medicine · Health Sciences

34h-index5.8kcitations186works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(65), Endometrial and Cervical Cancer Treatments(40), PARP inhibition in cancer therapy(27), Cancer Genomics and Diagnostics(18), Angiogenesis and VEGF in Cancer(12)

Publications186 total

Benchmarking the Current Landscape: Insights From an Association of American Cancer Institutes Survey on Academic Cancer Service Lines
JCO Oncology Practice·2025Open Access
Abstract A044: Application of HRDefine: a biomarker for identifying root causes of homologous recombination deficiency to a phase 3, randomized, placebo-controlled trial of veliparib in front-line treatment of advanced ovarian cancer (VELIA/GOG-3005)
Cancer Research·2025
1204P Feasibility of RNA-seq on FFPE tissues to identify survival-associated transcriptomic subtypes in ovarian cancer
Annals of Oncology·2025
Treatment tolerability associated with carboplatin dose based on actual versus adjusted body weight in patients with a body mass index ≥25 kg/m2 with advanced ovarian cancer
International Journal of Gynecological Cancer·2025· 3 citedOpen Access
Abstract P2-12-24: A phase I/Ib trial of the CDK4/6 antagonist ribociclib and the HDAC inhibitor belinostat in patients with metastatic triple negative breast cancer and recurrent ovarian cancer with response prediction by genomics (CHARGE)
Clinical Cancer Research·2025
Systemic Antifolate Chemotherapy Does Not Select for Fluconazole-Resistant Candida: A Multicenter Clinical Study
Pathogens·2025Open Access
SupplementaryGeneTable S1 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2025Open Access
Supplementary Material from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2025Open Access
PD-L1 targeted antibody-polymer-Epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer
Journal of Controlled Release·2025· 6 citedOpen Access
SupplementaryGeneTable S1 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2025Open Access
Supplementary Material from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2025Open Access
Figure 4 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2024Open Access
SupplementaryGeneTable S1 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2024Open Access
Figure 2 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2024Open Access
Table 1 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2024Open Access
Figure 1 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2024Open Access
Data from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2024Open Access
Figure 5 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2024Open Access
Figure 3 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2024Open Access
Supplementary Material from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2024Open Access
page 1 of 10Next →

Frequent Co-authors

David K. Gaffney(14), Deborah K. Armstrong(8), Ronald D. Alvarez(8), David M. Gershenson(8), Heidi J. Gray(8), Ardeshir Hakam(7), Steven W. Remmenga(7), Lainie P. Martin(6), Daniela Matei(6), David M. O’Malley(6), Charles A. Leath(5), Kian Behbakht(5), Lee-may Chen(5), Michael McHale(5), Sanja Percac‐Lima(5), Carolyn Johnston(5), Richard T. Penson(5), Paul Sabbatini(5), Mia Hashibe(5), Alison Fraser(5)